scholarly journals Monoclonal Immunoglobulin

10.5772/55855 ◽  
2013 ◽  
Author(s):  
Marie-Christine Kyrtsonis ◽  
Efstathios Koulieris ◽  
Vassiliki Bartzis ◽  
Ilias Pessah ◽  
Eftychia Nikolaou ◽  
...  
Keyword(s):  
Monoclonal Immunoglobulin

Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits

2015 ◽  
Vol 90 (5) ◽  
pp. 587-596 ◽  
Author(s):  
Gauri Bhutani ◽  
Samih H. Nasr ◽  
Samar M. Said ◽  
Sanjeev Sethi ◽  
Fernando C. Fervenza ◽  
...  
Keyword(s):  
Monoclonal Immunoglobulin ◽  
Immunoglobulin Deposits

scholarly journals Monoclonal Gammopathy of Renal Significance: Clinical and Histological Efficacy of a Bortezomib-Based Regimen

2020 ◽  
Vol 7 ◽  
Author(s):  
Giacomo Quattrocchio ◽  
Antonella Barreca ◽  
Antonella Vaccarino ◽  
Giulio Del Vecchio ◽  
Emanuele De Simone ◽  
...  
Keyword(s):  
Membranoproliferative Glomerulonephritis ◽  
Monoclonal Gammopathy ◽  
Filtration Rate ◽  
Estimated Glomerular Filtration Rate ◽  
Cell Clone ◽  
Dramatic Improvement ◽  
Complete Disappearance ◽  
Monoclonal Immunoglobulin ◽  
Immunotactoid Glomerulopathy ◽  
Chemotherapy Protocol

Monoclonal Gammopathy of Renal Significance (MGRS) is a group of heterogeneous disorders characterized by renal dysfunction secondary to the production of a monoclonal immunoglobulin by a nonmalignant B cell or plasma cell clone. We report the clinical and histological outcomes of two patients with biopsy-proven MGRS: one patient showed membranoproliferative glomerulonephritis with monoclonal k-light chain and C3 deposits, the second patient showed immunotactoid glomerulopathy. Both patients were treated with a 9-month chemotherapy protocol including bortezomib, cyclophosphamide, and dexamethasone. Renal biospy was repeated after 1 year. The estimated glomerular filtration rate (eGFR) increased from 22.5 (baseline) to 40 ml/min per 1.73 m2 after 12 months, then to 51.5 ml/min per 1.73 m2 after 24 months; proteinuria decreased from 4.85 (baseline) to 0.17 g/day after 12 months, then to 0.14 g/day after 24 months. Repeat renal biopsies showed a dramatic improvement of the glomerular proliferative lesions and near complete disappearance of the immune deposits. A bortezomib-based treatment proved very effective and was well-tolerated in the two patients presenting with clinically and histologically aggressive MGRS.

Sign in / Sign up

Export Citation Format

Share Document